FDA Approves At-Home Injection Start for Alzheimer's Drug Lecanemab

The U.S. FDA has approved a subcutaneous auto-injector for Leqembi (lecanemab-irmb), enabling patients with early Alzheimer's disease to begin their weekly treatment at home, a significant advancement for accessibility and patient convenience.

The top 3

1. 3 Key Disease-Modifying Drugs: Lecanemab (Leqembi) and Donanemab (Kisunla) are anti-amyloid therapies for early Alzheimer's, while Aducanumab (Aduhelm) received accelerated approval, all targeting beta-amyloid plaques.
2. Research Milestones: Key milestones include the identification of beta-amyloid plaques as a therapeutic target and the approval of Aducanumab in 2021 as the first new Alzheimer's treatment since 2003 to target an underlying cause.
3. Promising Candidates Next: Donanemab, developed by Eli Lilly, has shown positive Phase 3 trial results, significantly slowing cognitive and functional decline in early Alzheimer's disease, and is expected to be a key future treatment.

Sources

• FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease | AJMC
• FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment | NeurologyLive
• FDA Approves First At-home Starting Dose for Alzheimer's Disease Treatment | FDA
• LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - PR Newswire

Open the full topic